TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30713498
Drug: Immunoglobulin dose
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin dose escalation
Study: 30713538
Drug: Chimpanzee adenoviral
Normalized name: COVID-19 VACCINE ADENOVIRUS-26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimpanzee adenoviral vectors vaccine
Study: 30713786
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ONCOS-102 and pembrolizumab
Study: 30713786
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 µg or 400 µg)
Study: 30714202
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) plus clinical management
Study: 30716769
Drug: Compounded pain
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compounded pain creams for neuropathic pain (ketamine, gabapentin, clonidine, and lidocaine)
Study: 30716769
Drug: Compounded pain
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compounded pain creams for nociceptive pain (ketoprofen, baclofen, cyclobenzaprine, and lidocaine)
Study: 30716769
Drug: Compounded pain
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compounded pain creams for mixed pain (ketamine, gabapentin, diclofenac, baclofen, cyclobenzaprine, and lidocaine)
Study: 30716769
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (compounded pain creams)
Study: 30718242
Drug: Day 0
Normalized name: Apri 28-Day 0.03mg-0.15mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 0 to 100 mean glucose of 100 to 124 mg/dL
Study: 30718519
Drug: Inhaled corticosteroid/long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid/long-acting β agonists prescribed as per usual clinical practice
Study: 30718541
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) treatment
Study: 30720784
Drug: Park prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Park prescription intervention including an information pack, access to a weekly group exercise program in parks, and telephone counselling.
Study: 30721341
Drug: Avelumab 10
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 10 mg/kg every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal
Study: 30721554
Drug: High-sensitivity troponin
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity troponin (hscTnT) ≤ 5 ng/L
Study: 30721554
Drug: High-sensitivity troponin
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity troponin (hscTnT) > 50 ng/L
Study: 30721554
Drug: Natriuretic peptide
Normalized name: Natriuretic peptides b
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natriuretic peptide (NT-proBNP) ≤ 125 ng/L
Study: 30721554
Drug: Natriuretic peptide
Normalized name: Natriuretic peptides b
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natriuretic peptide (NT-proBNP) > 2,000 ng/L
Study: 30721917
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of acidified milk (800 g) containing 38.8 g lactose
Study: 30722097
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg azithromycin thrice weekly for 12 weeks
Study: 30723079
Drug: Serum levels
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum levels of TARC, MDC, and IL-10 after therapy
Study: 30723079
Drug: Serum levels
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum levels of TARC and IL-10 after therapy
Study: 30723727
Drug: Observational study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observational study data collection including clinical assessments, spirometry, biospecimens, patient-reported outcomes (PROs), and healthcare utilization (HCU) collected yearly and 3-monthly.
Study: 30724734
Drug: EA-230 (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA-230 (90 mg/kg/hour)
Study: 30724759
Drug: Once-daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral extended-release bupropion (BRP, Welbutrin XL, 450 mg/day)
Study: 30724759
Drug: Smartphone video
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone video dosing
Study: 30725293
Drug: Tenofovir Disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir Disoproxil Fumarate (TDF) therapy for 144 weeks
Study: 30756308
Drug: BI 853520
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 853520 200 mg QD
Study: 30726175
Drug: Pembrolizumab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (2 mg/kg every 3 weeks for up to 2 years)
Study: 30727950
Drug: Male partners
Approvals — FDA: no, EMA: no, PMDA: no
Description: Male partners receiving syphilis notification and treatment after partner notification by infected pregnant women.
Study: 30728310
Drug: robot-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: robot-based therapy targeting finger movements with enhanced proprioceptive feedback for 3 weeks
Study: 30729531
Drug: CD19-directed CAR
Normalized name: Allogeneic gene-edited CD19-directed CAR T cells/azercabtagene zapreleucel
DrugBank: Azercabtagene zapreleucel (DB17185)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19-directed CAR T-cell therapy
Study: 30729531
Drug: Precollection platelets
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precollection platelets (every 10 × 10^9/L increase)
Study: 30730411
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors in cancers with increased tumor mutational burden
Study: 30731276
Drug: Durvalumab 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 10 mg/kg intravenously every 2 weeks for 12 months
Study: 30733270
Drug: Twice-weekly carfilzomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly carfilzomib at 27 mg/m2
Study: 30733270
Drug: Twice-weekly carfilzomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly carfilzomib at 56 mg/m2
Study: 30734042
Drug: Endovascular thrombectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular thrombectomy plus standard medical therapy
Study: 30735255
Drug: Acute intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute intravenous alcohol infusion
Study: 30735474
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine adoption at no-cost
Study: 30735474
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine adoption with cost (25€ per person)
Study: 30736852
Drug: Allogenic γδ
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogenic γδ T cell immunotherapy (8 infusions from August 2017 to February 2018)
Study: 30738407
Drug: CoGNIT (Computerized
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoGNIT (Computerized General Neuropsychological INPH Test) administered preoperatively and at a postoperative follow-up 4 months after shunt surgery
Study: 30739366
Drug: Ruzasvir 60
Normalized name: Ruzasvir
DrugBank: Ruzasvir (DB11713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruzasvir 60 mg plus Uprifosbuvir 450 mg
Study: 30739576
Drug: Adjunctive perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive perampanel oral suspension (≤0.18 mg/kg/d)
Study: 30740545
Drug: Neuromuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular electrical stimulation (NMES) treatments lasting 20-45 minutes twice weekly for 2-4 months during feeding therapy sessions by a trained occupational therapist (OT).
Study: 30741382
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide extended-release (TA-ER) injection
Study: 30741812
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (400 mg once a day)
Study: 30742211
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin (n=1414)
Study: 30742211
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (n=1422)
Study: 30742566
Drug: Duvelisib 25
Normalized name: duvelisib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duvelisib 25 mg orally twice daily in 28-day cycles until progression, unacceptable toxicity, or death
Study: 30742776
Drug: Simultaneous practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous practice of diet, art, and biofield therapy
Study: 30742776
Drug: Biofield therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofield therapy
Study: 30743197
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of microcephaly and major ultrasound abnormalities
Study: 30744442
Drug: Minocycline (Tier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (Tier 1: 800 mg loading dose followed by 200 mg BID for 7 days)
Study: 30744442
Drug: Minocycline (Tier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (Tier 2: 800 mg loading dose followed by 400 mg BID for 7 days)
Study: 30745090
Drug: Tisotumab vedotin
Normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tisotumab vedotin 2.0 mg/kg intravenously once every 3 weeks (recommended phase 2 dose)
Study: 30745090
Drug: Tisotumab vedotin
Normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tisotumab vedotin 2.0 mg/kg intravenously once every 3 weeks
Study: 30745365
Drug: Autologous lymphocyte
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous lymphocyte infusion combined with peri-autoSCT immunotherapy with recombinant MAGE-A3 and adjuvant
Study: 30746241
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose from CBCT
Study: 30746608
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 110 mg BID (DE110)
Study: 30746608
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 150 mg BID (DE150)
Study: 30746608
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from Warfarin to Dabigatran
Study: 30747243
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous IL-2 (125,000 IU/kg/day, maximum 9-10 doses over 2 weeks)
Study: 30747243
Drug: Non-myeloablative lymphodepleting
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-myeloablative lymphodepleting chemotherapy, TIL, and low-dose IL-2
Study: 30747243
Drug: TIL infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TIL infusion product monitoring
Study: 30747273
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs), hydroxyapatite (HA) granules, bone morphogenetic protein-2 (BMP-2), and mechanical stabilization
Study: 30747719
Drug: Incentives for
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Incentives for adherence to antidepressant medications in the first 6 weeks of treatment (Project 1: ADAPT)
Study: 30753549
Drug: Tryptophan intake
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tryptophan intake ranging from 0.5 to 9.75 mg.kg-1.d-1
Study: 30753611
Drug: IMA950/poly-ICLC vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMA950/poly-ICLC vaccine
Study: 30753685
Drug: Dietary supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplements (DS)
Study: 30755498
Drug: Pressurised intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurised intraperitoneal aerosol chemotherapy (PIPAC)
Study: 30755498
Drug: PIPAC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIPAC treatment response
Study: 30755907
Drug: Obinutuzumab (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obinutuzumab (initial test dose)
Study: 30756297
Drug: 100% pasteurized
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% pasteurized watermelon juice (360 ml)
Study: 30756308
Drug: BI 853520
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 853520 200 mg once daily (QD)
Study: 30758653
Drug: ab interno
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ab interno subconjunctival gelatin implant (phaco + implant)
Study: 30758653
Drug: ab interno
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ab interno subconjunctival gelatin implant (implant alone)
Study: 30760105
Drug: Repeatedly measured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeatedly measured biomarkers (suppression of tumorigenicity-2, galectin-3, galectin-4, growth differentiation factor-15, matrix metalloproteinase-2 and 9, tissue inhibitor metalloproteinase-4, perlecan, cathepsin-D, cystatin-B)
Study: 30760246
Drug: Biomarkers measuring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarkers measuring cancer risk (insulin resistance, inflammation, oxidative stress)
Study: 30760466
Drug: Pracinostat 60
Normalized name: Pracinostat
DrugBank: Pracinostat (DB05223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pracinostat 60 mg/d, 3 d/wk for 3 consecutive weeks plus azacitidine 75 mg/m²
Study: 30761059
Drug: Adapted cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted cognitive behavioral treatment
Study: 30761078
Drug: Smart Device
Normalized name: benzalkonium chloride Topical Foam [Smart San]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smart Device System (SDS) including smartphone-based questionnaires, two smartwatches, and tablet-based Archimedean spirals drawing
Study: 30762508
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg once daily)
Study: 30764793
Drug: HPP patients
Normalized name: 4-HPP
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HPP patients (regardless of prior or current treatment)
Study: 30764800
Drug: High indoxyl
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High indoxyl sulfate (IS) group (IS level ≥ 2.74 μg/ml)
Study: 30764800
Drug: Low indoxyl
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low indoxyl sulfate (IS) group (IS level < 2.74 μg/ml)
Study: 30764800
Drug: Indoxyl sulfate
Normalized name: SULFATE
DrugBank: Indoxyl sulfate (DB07992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoxyl sulfate level ≥ 2.74 μg/ml
Study: 30765123
Drug: Direct-acting antivirals
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antivirals
Study: 30765258
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg every 3 weeks) plus trastuzumab (6 mg/kg) in phase 2
Study: 30765258
Drug: Pembrolizumab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (2 mg/kg and 10 mg/kg every 3 weeks) plus trastuzumab (6 mg/kg) in phase 1b
Study: 30766492
Drug: Vortioxetine, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine, dosage and duration not available
Study: 30767431
Drug: cfDNA from
Approvals — FDA: no, EMA: no, PMDA: no
Description: cfDNA from combination of plasma, sputum, and urine
Study: 30767706
Drug: Isoniazid (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid (dosage not specified)
Study: 30767706
Drug: Rifampicin (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (dosage not specified)
Study: 30768838
Drug: elbasvir/grazoprevir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: elbasvir/grazoprevir treatment after recipient HCV was first detected
Study: 30770221
Drug: MenB-FHbp vaccine
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenB-FHbp vaccine (120 μg) administered in various schedules (0-, 1-, 6-month; 0-, 2-, 6-month; 0-, 6-month; 0-, 2-month; or 0-, 4-month)
Study: 30770221
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of MenB-FHbp vaccine administered 48 months after primary vaccination
Study: 30770310
Drug: avalglucosidase alfa
Normalized name: Avalglucosidase alfa
DrugBank: Avalglucosidase alfa (DB16099)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: avalglucosidase alfa 5 mg/kg
Study: 30770310
Drug: avalglucosidase alfa
Normalized name: Avalglucosidase alfa
DrugBank: Avalglucosidase alfa (DB16099)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: avalglucosidase alfa 10 mg/kg
Study: 30770310
Drug: avalglucosidase alfa
Normalized name: Avalglucosidase alfa
DrugBank: Avalglucosidase alfa (DB16099)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: avalglucosidase alfa 20 mg/kg
Study: 30770348
Drug: Navoximod (GDC-0919)
Normalized name: calcium carbonate
DrugBank: Navoximod (DB15439)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Navoximod (GDC-0919) in combination with PD-L1 inhibitor Atezolizumab
Study: 30770534
Drug: Wild-type influenza
Normalized name: Influenza A virus A/Brisbane/10/2010 (H1N1) wild type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wild-type influenza A(H3N2)2011 virus (any dose)
Study: 30771200
Drug: DSF/Cu (disulfiram
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSF/Cu (disulfiram and copper) plus standard monthly temozolomide (TMZ) 80 mg PO TID and Cu 1.5 mg PO TID
Study: 30772821
Drug: Cooled radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooled radiofrequency ablation (CRFA) after intra-articular steroid injection (IAS)
Study: 30772864
Drug: Vaccination against
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination against five vaccine targets (pneumococcus, hepatitis B virus, etc.), specific details on dosage and duration not available.
Study: 30772905
Drug: Daily wild
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily wild blueberry consumption for 1 month
Study: 30772905
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of anthocyanin metabolites in mice
Study: 30772905
Drug: Daily wild
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily wild blueberry consumption
Study: 30773463
Drug: BCL-2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BCL-2 inhibitor ABT-199
Study: 30774399
Drug: Initial antibiotic
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial antibiotic therapy (IAT; antibiotics administered ≤48 hours post-initiation of antibiotic therapy)
Study: 30774635
Drug: Liposome-based vaccines
Normalized name: covid-19, RNA-based vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome-based vaccines
Study: 30776363
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 1.5 mg of paclitaxel
Study: 30776452
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg/d for 12 months
Study: 30777022
Drug: 22 weekly
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 22 weekly group sessions called School of Health for Older People
Study: 30777049
Drug: Patient education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education and exercise therapy (group-based program with 2 sessions of education and 8 weeks of supervised exercises)
Study: 30777875
Drug: Alisertib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib (80 mg/m2)
Study: 30778280
Drug: rTMS combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTMS combined with Intensive Language-Action Therapy
Study: 30778345
Drug: Subcutaneous Immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®])
Study: 30778520
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel for 13 weeks combined with trastuzumab-pertuzumab in molecular non-responders
Study: 30780166
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion (0.01, 0.05, 0.10 and 0.15 µg/kg/min; 15 minutes at each step)